Achilles Therapeutics 주식 (NASDAQ: ACHL)

에 대한 최신 뉴스 Achilles Therapeutics (NASDAQ:ACHL) 주식

Achilles Therapeutics

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Equities

News

Markets

Movers

General

ACHL

아킬레스 테라퓨틱스(NASDAQ:ACHL)의 주식은 회사가 아스트라제네카(NASDAQ:AZN)와 1,200만 달러 규모의 계약을 발표하고, 일자리 감축 계획을 밝힌 후 화요일 16% 이상 급등했다. 이번 계약은 아킬레스의 TRACERx 비소세포폐암(NSCLC) 연구로부터 데이터와 종양 샘플에 대한 상업적 라이선스 이전을 아스트라제네카에 허용하는 내용을 포함하고 있다.

아킬레스 테라퓨틱스: $1,200만 아스트라제네카와의 계약 발표, 직원 감축 발표 후 주가 급등

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics PLC

Concerns are rising over the safety of smartwatch bands after a new study identified the presence of hazardous chemicals in these popular accessories.
What Happened: A recent study published in the journal Environmental Science &amp; Technology Letters has discovered that smart watch bands may contain harmful substances. These bands, often made from synthetic rubber known as fluoroelastomers, can include perfluorohexanoic acid (PFHxA), a type of &#8220;forever chemical,&#8221; Salon <a href="https://www.salon.com/2024/12/24/forever-chemicals-could-be-entering-your-body-from-smart-watch-bands-study-finds/">reported</a> on Thursday,
PFHxA is part of a group of industrial compounds called&nbsp;per and polyfluoroalkyl substances (PFAS),&nbsp;which are resistant to degradation. These chemicals have been associated with serious health issues, including cancer and infertility. Despite the risks, PFAS are commonly found in various consumer products such as non-stick cookware and water-resistant fabrics.
The study, led by&nbsp;Graham F. Peaslee&nbsp;from&nbsp;the University of Notre Dame,&nbsp;analyzed 22 watch bands from different brands and price ranges. Surprisingly, PFHxA was the most frequently detected compound. Peaslee noted that the public might not&nbsp;recognize fluoroelastomers as a type&nbsp;of PFAS, leading to unintentional exposure.
See Also:&nbsp;<a href="https://www.benzinga.com/24/12/42666163/iphone-17-pro-could-retain-iconic-triangular-camera-design-despite-rumors-of-a-radical-horizontal-layout?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">iPhone 17 Pro To Retain Iconic &#8216;Triangular&#8217; Camera Layout Despite Rumors Of Radical Horizontal Layout</a>
Although the study did not involve human testing, the researchers warned that high PFAS levels in these bands could lead to significant skin absorption, especially during activities involving sweat and open pores.
Why It Matters: The revelation of toxic chemicals in smart watch bands comes at a time when the global wrist-worn device market is experiencing significant growth. <a href="https://www.benzinga.com/24/12/42570544/apple-watch-is-getting-a-run-for-its-money-as-chinese-tech-giants-led-by-huawei-lead-20-growth-in-global-wrist-worn-device-market">Chinese tech giants </a>are challenging the dominance of established players like&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). The global market saw shipments reach 139 million units in the first three quarters of 2024, with China leading the charge.
Additionally,&nbsp;Samsung Electronics Co Ltd&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) is intensifying its <a href="https://www.benzinga.com/news/24/07/39716525/samsung-takes-on-apple-with-new-galaxy-ring-and-watch-ultra">competition with Apple</a> by launching new wearables, including the Galaxy Ring and Watch Ultra. As the market expands, the potential health risks associated with PFAS in smart watch bands could become a significant concern for consumers and manufacturers alike.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42664762/after-investing-nearly-14-billion-in-openai-microsoft-reportedly-moves-to-reduce-its-dependence-on-chatgpt-parent?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Microsoft Invested Nearly $14 Billion In OpenAI But Now Its Reducing Its Dependence On The ChatGPT-Parent</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image: Shutterstock/ Usoltsev Kirill

AAPL

SSNLF

Your Smart Watch Band Might Contain Toxic, Cancer-Linked 'Forever Chemicals,' Study Reveals

WIIM

GameStop shares are trading higher. Retail trader 'Roaring Kitty' posted a picture of a Christmas present on X.

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) could ride the artificial intelligence boom, with its crown jewel iPhone expected to witness a "multi-year" upgrade cycle, according to an analyst.
What Happened: Tech bull and Wedbush analyst Dan Ives believes that Apple's iPhone sales could witness a boost thanks to AI.
"Raising price target on Apple to $325 as a golden era of growth for Cupertino is now on the horizon into 2025," said Ives in a post on X.
Apple stock closed at $258.20 on Tuesday, up 1.2% for the day. Year-to-date, Apple shares have gained 39%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. Ives&#8217; $325 price target implies a 26% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26081608/Screenshot-2024-12-26-at-6.46.00%E2%80%AFPM-1024x385.png" alt="" class="wp-image-707606" /></a></figure>
While Apple has been a little late to the AI game, having been beaten by its rivals Alphabet Inc.'s Google, and Samsung Electronics Co. Ltd., <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">the Cupertino-based company unveiled</a> the Apple Intelligence suite of AI features with the iPhone 16 series in September.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Ives expects Apple to benefit significantly from the consumer AI revolution, positioning it for substantial growth through 2025.
"We believe Apple is heading into a multi-year AI driven iPhone upgrade cycle still being underestimated by the Street."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Raising price target on Apple to $325 as a golden era of growth for Cupertino is now on the horizon into 2025. We believe Apple is heading into a multi-year AI driven iPhone upgrade cycle still being underestimated by the Street. The consumer AI Revolution goes thru &#x1f34e; &#x1f525;&#x1f402;&#x1f34e;&#x1f34f;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1872250576370913362?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/tech/24/12/42641667/is-this-nancy-pelosis-stock-pick-set-to-overtake-nvidia-ai-chip-race-to-heat-up-by-2025-as-meta-and-microsoft-look-beyond-jensen-huangs-chip-maker-says-expert?itm_source=parsely-api">Is This Nancy Pelosi&#8217;s Stock Pick Set To Overtake Nvidia?</a>
Why It Matters: The recent price target hike aligns with <a href="https://www.benzinga.com/markets/equities/24/12/42664887/apples-near-term-success-will-be-driven-by-strong-holiday-season-iphone-16-says-dan-ives-analyst-sees-stock-hitting-300-cupertino-hitting-4-trillion-marketcap">Ives' previous predictions</a>, which foresees Apple reaching a $4 trillion market capitalization by early 2025. This projection is driven by strong iPhone sales and AI innovations.
Recent supply chain checks in Asia indicate robust iPhone 16 upgrade trends, particularly during the holiday season. Ives believes that the success of the iPhone 16 will serve as a launchpad for a renaissance of growth in Cupertino over the next 12 to 18 months.
Furthermore, <a href="https://www.benzinga.com/markets/equities/24/12/42477035/dan-ives-predicts-apple-to-ship-record-240-million-iphones-in-2025-sparking-multi-year-supercycle-as-ai-integration-drives-growth">Ives predicts</a> that Apple will ship a record 240 million iPhones in 2025, setting a new annual record as AI features in the iPhone 16 spark a &#8220;multi-year supercycle.&#8221; This projection underscores the significance of AI integration in consumer devices, with Apple Inc. leading the charge.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42642020/steve-ballmers-bold-investment-strategy-80-of-his-portfolio-is-in-microsoft-stock-heres-why-his-keep-it-simple-approach-is-winning-big?itm_source=parsely-api">Steve Ballmer&#8217;s Winning Investment Strategy: Billionaire Says &#8216;Keep It Simple&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Pexels

Analyst Color

Price Target

Tech

Tech Bull Predicts 26% Upside For Apple Stock, Sees 'Golden Era Of Growth' For Cupertino Due To Multi-Year AI-Driven iPhone Upgrade Cycle

CHEK

Check-Cap Approves $6M Loan To Nobul AI From Segregated Account At 5% Annual Interest To Support Acquisition Targets And Growth Initiatives, With Repayment Linked To Business Combination Outcome

COEP

Coeptis Therapeutics Acquires NexGenAI Affiliates Network Platform And Launches Coeptis Technologies To Drive AI Innovation In Biotech And Technology, Expanding Growth Potential With Advanced Marketing And Automation Tools

TScan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42681377/tscan-therapeutics-announces-30-million-registered-direct-offering-at-a-37-premium" rel="noreferrer noopener">premarket session on Thursday.</a>
The firm announced a significant financing deal, entering into a securities purchase agreement with Lynx1 Capital Management LP and an investment fund advised by Lynx1.
Under the agreement, TScan will sell approximately $30 million in pre-funded warrants, which are exercisable for up to 7.50 million shares of its voting common stock.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, TCRX stock has lost over 51% in the past year.&nbsp;
Each warrant will be priced at $4.00, with an exercise price of $0.0001 per share.
This deal represents a 37% premium over TScan&#8217;s last closing price and a 34% premium compared to its 10-day volume-weighted average closing price. The financing is expected to close by December 27, 2024, pending customary closing conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42681352/us-futures-tumble-after-christmas-break-but-analysts-still-expect-a-santa-claus-rally" rel="noreferrer noopener">US Stocks Likely To Open In Red After Christmas Break But Analysts Still Expect A Santa Rally Into The New Year</a>
Gavin MacBeath, Ph.D., CEO of TScan Therapeutics, expressed appreciation for Lynx1&#8217;s continued support, highlighting the investment as a testament to their commitment to TScan&#8217;s mission of delivering life-changing TCR-T cell therapies for cancer patients.
Jason A. Amello, CFO of TScan, added that the additional $30 million in gross proceeds will extend the company&#8217;s cash runway, now expected to fund operations into the first quarter of 2027, up from the previous expectation of the fourth quarter of 2026.
This funding comes after TScan filed a registration statement with the SEC in November 2022, which was declared effective in May 2023.
Price Action: TCRX shares are trading higher by 16.8% to $3.40 premarket at last check Thursday.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678014/top-7-blue-chip-stocks-with-the-best-return-potential-going-into-2025" rel="noreferrer noopener">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq's Surge</a>
Photo via Shutterstock.

Health Care

Offerings

TCRX

Why Is TScan Therapeutics Stock Gaining Today?

WISA

WiSA Technologies Signs Definitive Agreement To Acquire CompuSystems, Anticipating $13M-$15M Revenue And $3M-$4M EBITDA In 2025; Acquisition Enhances Event Data Monetization And Activates ADIO Technology For 1.4M Attendees; Conference Call Scheduled For December 30, 2024, At 11 AM ET; Financial Terms Not Disclosed

Despite bearish price action, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has seen a significant uptick in whale activity, fueling speculation of <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">an impending bullish phase</a> among traders.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.3167&nbsp;</td>
<td>$46.7 Billion</td>
<td>-4.2%&nbsp;</td>
<td>-12.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002171</td>
<td>$12.8 Billion</td>
<td>-5.4%</td>
<td>-9.7%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001738  </td>
<td>$7.3 billion</td>
<td>-6.9%&nbsp;</td>
<td>-9.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Javon Marks <a href="https://x.com/JavonTM1/status/1871995033685311804">highlighted</a> historical patterns, suggesting Dogecoin could rise beyond the 1.618 Fibonacci Extension level, as it has in previous cycles. If this scenario repeats, DOGE could surge by 570%, reaching $2.28 or higher.
Crowtrades remains confident, declaring &#8220;$1 is a promise.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dogecoin to $1 ain&#39;t a meme, it&#39;s a promise.<a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> <a href="https://t.co/gpgMnwQEwZ">https://t.co/gpgMnwQEwZ</a> <a href="https://t.co/vy2JAwG8Bu">pic.twitter.com/vy2JAwG8Bu</a>
&mdash; CROW (@TheCrowtrades) <a href="https://twitter.com/TheCrowtrades/status/1871824957715681664?ref_src=twsrc%5Etfw">December 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Tardigrade, another trader, <a href="https://x.com/TATrader_Alan/status/1871823205708738568">observed</a> consolidation patterns similar to those preceding Dogecoin's January 2021 pump. He predicts that January 2025 could mark another explosive breakout.
Statistics: Coinglass data shows Dogecoin's short liquidations of $845,000 are the lowest since Oct. 25.
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1871651560540762452">noted</a> in a post on X on Wednesday that whales purchased 270 million DOGE over the past four days. This raises curiosity among traders if significant whale movement implies an upcoming bull run for the meme coin.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42645811/dogecoin-shiba-inu-could-underperform-stronger-cryptos-trader-warns-heres-why">Dogecoin, Shiba Inu Could Underperform Stronger Cryptos, Trader Warns: Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Price Down 4%: What Is Going On?

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.69</td>
<td align="right">0.05</td>
<td align="right">0.05</td>
<td>4.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">134.20</td>
<td align="right">0.04</td>
<td align="right">0.02</td>
<td>295</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">97.88</td>
<td align="right">-1.29</td>
<td align="right">-1.31</td>
<td>526</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.09</td>
<td align="right">-0.35</td>
<td align="right">-0.45</td>
<td>2.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.18</td>
<td align="right">-0.30</td>
<td align="right">-0.40</td>
<td>1.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">138.83</td>
<td align="right">-0.49</td>
<td align="right">-0.36</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.68</td>
<td align="right">-0.85</td>
<td align="right">-0.36</td>
<td>3.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.86</td>
<td align="right">-0.13</td>
<td align="right">-0.27</td>
<td>16.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">234.36</td>
<td align="right">-0.11</td>
<td align="right">-0.05</td>
<td>180</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 26, 2024

Toyota shares are trading higher following a recent report suggesting the company is seeking a 20% return-on-equity target. The stock may also be reacting to the Nissan-Honda merger agreement.

Biotech

ASMB

Assembly Biosciences Reports Interim Phase 1b Results From Trial Evaluating ABI-4334 In Chronic Hepatitis B; Says ABI-4334 Was Well Tolerated And Showed Mean Reduction Of 2.9 log IU/mL In Plasma HBV DNA Over 28 Days Of Treatment

Delivering 5x Power Efficiency Boost For AI And Blockchain, Showcasing Innovation In High-Performance Energy-Efficient Solutions

Nano Labs Unveils FPU3.0 ASIC Architecture With 3D DRAM Stacking

The reverse stock split will become effective at 12:01 a.m. Eastern Time on Monday, December 30, 2024, and the Company's common stock will commence trading on the Nasdaq on a post-split basis at the opening of the market on December 30, 2024, pending confirmation by the Depository Trust Company and the Nasdaq.&nbsp;
The Company expects that the reverse stock split, which was approved by the Company's stockholders on November 27, 2024, will increase the price per share of the Company's common stock, and is part of the Company's strategy to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq.
 &nbsp;

Stock Split

JNVR

Janover Plans To Effect 1-For-8 Reverse Stock Split Of Its Common Stock

Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) <a href="https://www.benzinga.com/24/12/42657620/amd-and-micron-top-analyst-picks-for-ai-and-next-gen-tech-growth">shares</a> have underperformed Nasdaq 100 despite gaining AI market share this year. Should you buy or sell the stock as its technical analysis indicates a downtrend? Here&#8217;s what analysts are saying about the stock. 
What Happened: The technical analysis of daily moving averages indicates a bearish trend.
The stock ended at $126.29 apiece on Tuesday. This was above its eight-day simple moving average of $123.48. However, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, its current stock price was lower than the 20-day moving average of $130.77, 50-day moving average of $140.38 and its 200-day moving average of $154.50.
This implies that the stock is in a downtrend. On the other hand, the relative strength index of 40.31 suggests the stock&#8217;s movement is neutral and it is not yet in an overbought or an oversold zone.
<figure class="wp-block-image size-large"><a href="pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071556/amd-chart-1024x576.png" alt="" class="wp-image-707497" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071556/amd-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071556/amd-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071556/amd-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071556/amd-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071556/amd-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/24/12/42680125/nvda-could-go-up-to-170-in-q1-after-breaching-145-level-as-traders-turn-bullish-on-jensen-huangs-ai-giant">NVDA Could Go Up To $170 In Q1 After Breaching $145 Level As Traders Turn Bullish On Jensen Huang&#8217;s AI Giant </a>
Why It Matters: AMD&#8217;s 2024 was mixed. New GPUs drove strong data center growth, gaining share against Nvidia&#8217;s H100 due to availability and pricing advantages. However, gaming and embedded segments decelerated, impacting overall growth.
According to <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">Benzinga</a>, AMD has a consensus &#8216;buy&#8217; with a price target of $195.07 based on the ratings of 30 analysts.
The highest price target out of all the analysts <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">tracked </a>by Benzinga is $265 issued by Melius Research with a &#8216;buy&#8217; rating on March 8. According to the analysts at Melius, AMD is mirroring Nvidia Corporation&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) past success. This is despite a recent price target increase, expected by market observers. While AMD&#8217;s growth is significant, it&#8217;s not seen as threatening Nvidia&#8217;s dominance. Nvidia&#8217;s broader ecosystem and market expansion benefit AMD by creating a larger market for high-performance AI chips.
AMD is one of <a href="https://www.benzinga.com/24/12/42657620/amd-and-micron-top-analyst-picks-for-ai-and-next-gen-tech-growth">Rosenblatt</a>'s top picks for the first half of 2025 on momentum in CPU and GPU share gains into 2025 and a broader non-AI recovery exiting 2025. The difference entering 2025 is that the Street acknowledges this dynamic, which has legs for double-digit market share in GPU compute and AI inference at the edge, being a secular opportunity on Xilinx incumbency and chiplet prowess.
The lowest target price was a downgrade from &#8216;buy&#8217; to &#8216;neutral&#8217; from BofA Securities. It was adjusted to $155 from $180 per share on Dec. 9. It predicts AMD will hold a small 4% of the $200 billion AI accelerator market in 2025, significantly trailing Nvidia&#8217;s dominant 80%+ share. This, coupled with potential PC processor market weakness in the first half of 2025, raises concerns for AMD&#8217;s future performance.
The average price target of $164.33 between Morgan Stanley, BofA Securities, and Mizuho implies a 30.81% upside for Nvidia.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/AMD/analyst-ratings"><img loading="lazy" decoding="async" width="943" height="361" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071348/AMD-ANR-.png" alt="" class="wp-image-707495" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071348/AMD-ANR-.png 943w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071348/AMD-ANR--300x115.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26071348/AMD-ANR--768x294.png 768w" sizes="(max-width: 943px) 100vw, 943px" /></a></figure>
Price Action: Shares of AMD were down 0.24% at $125.99 per share in premarket on Thursday. The stock was down 8.87% this year underperforming the Nasdaq 100, which rose by 31.76% this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678014/top-7-blue-chip-stocks-with-the-best-return-potential-going-into-2025">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq&#8217;s Surge</a></li>
</ul>
Image via Shutterstock

Downgrades

Technicals

Reiteration

Analyst Ratings

Trading Ideas

NVDA

Should You Buy or Sell This Nvidia Rival? Analysts Weigh In As Technicals Signal A Downtrend

Welltower's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) short percent of float has fallen 5.38% since its last report. The company recently reported that it has 10.09 million shares sold short, which is 2.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Welltower Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735218024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Welltower has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Welltower's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Welltower's peer group average for short interest as a percentage of float is 7.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

WELL

Looking Into Welltower's Recent Short Interest

Glaukos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) short percent of float has fallen 3.61% since its last report. The company recently reported that it has 2.57 million shares sold short, which is 7.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Glaukos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735218018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Glaukos has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Glaukos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Glaukos's peer group average for short interest as a percentage of float is 3.70%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GKOS

(GKOS) - Analyzing Glaukos's Short Interest

According to a report issued by Realtor.com, counties switching their presidential votes from Biden to Trump in 2024 might see accelerated home price growth over the next four years.
The report, drawn from a study by the Journal of Real Estate Research, examined home prices and presidential election results across six elections from 2000 to 2020. Data showed that flipping to successful nonincumbent candidates <a href="https://www.benzinga.com/real-estate/24/11/41747603/30-less-than-blue-swing-state-home-prices-align-with-red-states-says-realtor-com">outperformed other markets in home value appreciation</a>.
Realtor identified 84 counties nationwide that shifted from Biden in 2020 to Trump in 2024, ranging from Florida&#8217;s Miami-Dade County to Montana&#8217;s Blaine County along the Canadian border.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/go/arrived-private-credit-yf">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a></li>
</ul>
&#8220;These counties you identified could potentially experience superior housing performance following the election,&#8221; lead author Eren Cifci, assistant professor of finance at Austin Peay State University, told Realtor.com.
The pattern held regardless of political party. Areas supporting whichever nonincumbent candidate won the White House showed stronger price performance in subsequent years.
Federal spending often follows electoral shifts. &#8220;The rival party may recognize the critical role these counties played in securing their victory. Consequently, they might invest in these areas and work to improve living conditions to maintain voter support in future elections,&#8221; Cifci said.
Local engagement also drives growth. Communities voting for change often see increased civic participation, volunteerism and economic activity, which lift property values.
See Also: Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
The research found no notable price impacts in counties flipping to incumbent winners or losing candidates. Cifci emphasized the findings indicate potential trends rather than guarantees.
Current market conditions vary widely among the 84 counties. Georgia&#8217;s Baldwin County saw November median list prices rise 53% year-over-year to $356,250, while Florida&#8217;s Miami-Dade County dropped 9.2% to $634,000.
The study primarily focused on how home prices, rather than the reverse, influence elections. Counties with strong price appreciation supported incumbents, while underperforming markets favored challengers.
&#8220;People feel more financially wealthy if they have a lot of housing equity,&#8221; said co-author Alan Tidwell, associate professor at the University of Alabama. &#8220;How financially wealthy they feel really impacts their sense of financial and economic well-being.&#8221;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today. </a>Price swings <a href="https://www.benzinga.com/markets/24/12/42572520/2025-housing-market-looks-like-a-year-of-struggle-for-states-like-builders-now-hold-record-inventory?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate">show broad regional variation</a>. California&#8217;s Inyo County rose 4.9% to $562,450, while Montana&#8217;s Blaine County fell 43.79% to $120,000. Texas markets showed similar disparity – Culberson County jumped 75.71% to $264,450 as Hidalgo County declined 3.55% to $270,000.
The study tracked 84 counties across 27 states. Florida and Texas led with the most flipped counties at six and 10 respectively. California followed with seven counties switching their presidential preference.
Historical data suggests infrastructure spending increases often follow changes in voting patterns. Past election cycles saw upticks in road improvements, federal construction projects and housing development in areas that helped secure presidential victories.
Market analysts note the findings align with broader economic patterns linking political shifts to regional development. However, local market conditions, employment rates and population growth remain primary drivers of home values.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

84 Counties That Flipped To Trump Could See Home Prices Rise Faster

PulteGroup's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) short percent of float has fallen 11.82% since its last report. The company recently reported that it has 4.59 million shares sold short, which is 2.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PulteGroup Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735218012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PulteGroup has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PulteGroup's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PulteGroup's peer group average for short interest as a percentage of float is 10.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into PulteGroup's Recent Short Interest

This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.
Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents. The VA and Emory University have granted Hoth this license to further develop the technology with the goal of ensuring the benefits of this innovation are accessible to the widest audience possible.
Hoth has also entered into an agreement to further protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its lead therapeutic HT-001. The additional intellectual property expands HT-001's reach to other cancer therapeutics.

HOTH

Hoth Therapeutics Enters Exclusive Patent License Agreement With US Department Of Veterans Affairs

Morgan Stanley analyst Eric Serotta maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Equal-Weight and maintains $42 price target.

CELH

Morgan Stanley Maintains Equal-Weight on Celsius Holdings, Maintains $42 Price Target

Achilles Therapeutics GAAP EPS of -$0.41

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) just reported results for the second quarter of 2024.<ul><li>Achilles Therapeutics reported earnings per share of -41 cents. This met the analyst estimate for EPS of -41 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/achl-stock-earnings-achilles-therapeutics-for-q2-of-2024/">ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHI...

Achilles Therapeutics Shifts Strategy, Seeks Alternatives

Achilles climbs after decision to find strategic alternatives

Achilles Therapeutics GAAP EPS of -$0.48

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, ...

Achilles Therapeutics Explores Strategic Options Amid Financial Update

Achilles Therapeutics Plc ( ($ACHL) ) has released its Q3 earnings. Here is a breakdown of the information Achilles Therapeutics Plc presented to i...

Achilles Therapeutics Reports Q3 2024 Financial Results

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has successfully regained compliance with Nasdaq's minimum bid price req...

Achilles Therapeutics Regains Nasdaq Compliance, Boosting Investor Confidence

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Canc...

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics sells technology assets to AstraZeneca

AZNCF

Press Releases

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Earnings

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Achilles Therapeutics Announces Strategic Update

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

ARCT

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

AlloVir

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CEL-SCI

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech

FibroGen

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Gain Therapeutics

Kezar Life Sciences

MAIA Biotechnology

Omega Therapeutics

Passage Bio

Q32 Bio

Serina Therapeutics

Spero Therapeutics

Shattuck Labs

Exicure

Xilio Therapeutics

Piper Sandler

Chardan Capital

B of A Securities

아킬레스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>)의 주식은 회사가 아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)와 1,200만 달러 규모의 계약을 발표하고, <a href="https://www.benzinga.com/pressreleases/24/12/g42669546/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">일자리 감축 계획</a>을 밝힌 후 화요일 16% 이상 급등했다.
이번 계약은 아킬레스의 TRACERx 비소세포폐암(NSCLC) 연구로부터 데이터와 종양 샘플에 대한 상업적 라이선스 이전을 아스트라제네카에 허용하는 내용을 포함하고 있다.
이 백만 달러 규모의 거래는 아킬레스의 전략적 검토 결정을 마무리짓는 신호로, 이는 2024년 9월에 발표된 바 있다.
거래 완료 후 아킬레스는 직원 수를 줄이고 이사회의 규모를 축소할 계획을 밝혔으며, 이는 나스닥 및 미 증권거래위원회(SEC) 요구사항을 준수하는 범위 내에서 진행된다.
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div> </div>
</div>
</div>
</div>
&#8220;아킬레스는 이제 추가 조치를 취할 계획이며, 여기에는 직원 수의 추가 감소와 이사회의 규모 축소가 포함된다. 이는 나스닥 및 SEC 요구사항을 준수하는 범위 내에서 이루어질 것이다&#8221;고 이 회사가 언급했다.
추가 읽기: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">아메리칸 항공, 크리스마스 이브 비행 중단 해제, 주가 반등</a>
TRACERx 연구는 런던 대학교(UCL)의 찰스 스완튼(Charles Swanton) 교수의 주도로 진행되었으며, 800명 이상의 폐암 환자로부터 3,200개 이상의 종양 샘플에서 광범위한 유전적 데이터를 수집했다.
이 다지역, 다시간점 시퀀싱 연구는 암의 진화와 치료 반응에 대한 깊은 통찰력을 제공한다.
계약의 일환으로 아스트라제네카는 또한 아킬레스의 물질 획득 플랫폼(MAP)을 인수하게 되며, 이 플랫폼은 폐암, 흑색종, 유방암 등 다양한 고형 종양 적응증에서 수집된 거의 300명의 암 환자 종양 샘플과 데이터를 포함하고 있다.
&#8220;종양학 분야의 선두주자인 아스트라제네카가 우리의 TRACERx와 MAP 자산의 과학적 가치를 인정해 주셔서 기쁘다&#8221;라고 이라지 알리 박사(Dr. Iraj Ali), 아킬레스 테라퓨틱스의 CEO가 말했다.
이 회사는 이러한 자산들이 개선된 암 치료제 개발에 상당한 잠재력을 가지고 있다고 믿고 있다.
가격 동향: ACHL 주식은 화요일16.17% 승승한 $1.14로 마감했다. 이후 시간외 거래에서 1.75% 추가 상승했다.
 
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire" target="_blank" rel="noreferrer noopener">마이크로스트레티지, 나스닥 100 포함 후 하락: 비트코인 베팅 논란?</a></li>
</ul>
사진 출처: Johaehn from Pixabay


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Achilles Therapeutics

뉴스

에 대한 최신 뉴스 Achilles Therapeutics (NASDAQ:ACHL) 주식

수요일, 12월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌